Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02129270
Other study ID # 158-13-EMC
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date May 2014
Est. completion date August 2018

Study information

Verified date February 2020
Source HaEmek Medical Center, Israel
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to Prove that injection of 15 to 20 mL of lidocaine 1% into the fracture site (Hematoma block) is more effective in terms of pain relieving then injection of 10 mL of lidocaine 2%, and equally safe in terms of complications, for closed reduction of distal radius fractures.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date August 2018
Est. primary completion date February 2015
Accepts healthy volunteers No
Gender All
Age group 15 Years and older
Eligibility Inclusion Criteria:

- Patients with Fractures of the distal radius, with or without ulna fracture

Exclusion Criteria:

- Children,

- pregnant women,

- patients with infection or suspected infection on the site for injection.

- Patients whose condition requires general anesthesia (patients with more fractures other than the distal radius and ulna, patients with many damage...)

Study Design


Intervention

Drug:
Lidocaine HCl 2% .
comparison of different dosages of drug
Lidocaine HCl 1%
comparison of different dosages of drug

Locations

Country Name City State
Israel HaEmek medical center Afula

Sponsors (1)

Lead Sponsor Collaborator
HaEmek Medical Center, Israel

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary This study will be measured effective in terms of pain relieving with Visual Analog Scale. 1 year
Secondary This study will be measured safe in terms of complications to injection. Number of Participants with Adverse Events as a Measure of Safety and Tolerability. 1 year